Article
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
JAMA oncology - 1 Aug 2018
Aguiar Pedro N, Haaland Benjamin, Park Wungki, San Tan Pui, Del Giglio Auro, de Lima Lopes Gilberto
Abstract excerpt
Importance: The survival of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the last decade with the development of targeted tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation TKI that is approved by the US Food and Drug Administration for the treatment of patients who develop EGFR T790M mutations,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.